Showing results (1-10 of 49) with videos related to
Sort By:
Pageof 5
The Oncologist|September 15, 2006
Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancerJosé Baselga, Edith A Perez, Tadeusz Pienkowski, et al.Clinical Chemistry and Laboratory Medicine|September 9, 2006
Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patientsMalgorzata Fuksiewicz, Janina Kaminska, Beata Kotowicz, et al.Clinical Chemistry and Laboratory Medicine|June 29, 2010
Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancerMalgorzata Fuksiewicz, Maria Kowalska, Beata Kotowicz, et al.Oncology|November 20, 2010
A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancerAgnieszka Jagiello-Gruszfeld, Sergei Tjulandin, Natalya Dobrovolskaya, et al.Croatian Medical Journal|August 20, 2011
Cancer epidemiology in Central, South and Eastern European countriesEduard Vrdoljak, Marek Z Wojtukiewicz, Tadeusz Pienkowski, et al.Onkologie|September 12, 2009
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trialJacek Jassem, Tadeusz Pienkowski, Anna Pluzanska, et al.Cancer Chemotherapy and Pharmacology|August 12, 2009
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanesAlison Jones, Mary O'Brien, Harald Sommer, et al.The Lancet. Oncology|August 14, 2012
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialGustavo Ismael, Roberto Hegg, Susanne Muehlbauer, et al.The Oncologist|August 9, 2012
Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancerAnna J Zaczek, Aleksandra Markiewicz, Barbara Seroczynska, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival studyBrian Leyland-Jones, Vladimir Semiglazov, Marek Pawlicki, et al.Pageof 5